Replies to post #242718 on Biotech Values

[Biowatch]

POAI seems to have many problems.

From your citation:

To describe stock ticker POAI’s last 12 months as “volatile” doesn’t do it justice. 2021 consisted of 9 dilutive offerings, two quarter long blackout periods (with no corresponding announcement after), multiple botched press releases by an investor relations firm offering little in the way of explanation

I seriously doubt that if you work for any sort of research center that they let you walk away with the rights to benefit from anything you “invented” while you worked there, so I wonder about the validity and worth of any patent that this post claims will make them viable.

GLG Pharma LLC is private company, so more difficult to to research.

POAI has a market cap around $39 million, and traded between $0.249 and $1.64 a share over the last year, so while not exactly a penny stock, it’s close to it.

The Yahoo Finance description of their business is

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States.

This ticks most of the current trendy boxes, especially “personalized” and “AI” and “knowledge driven.” Yes, it would be great if we could know exactly how to give every individual patient the precise cocktail of medicine that would serve them best to defeat the particular flavor of cancer that afflicts them, but I don’t see how this post about an old patent has anything to do with it.